Thalidomide enhanced the efficacy of CHOP chemotherapy in the treatment of diffuse large B cell lymphoma: A phase II study

Oncotarget

Volumn 7, Issue 22, 2016, Pages 33331-33339

  Ji, Dongmei ^a   Li, Qiu ^b   Cao, Junning ^a   Guo, Ye ^a   Lv, Fangfang ^a   Liu, Xiaojian ^a   Wang, Biyun ^a   Wang, Leiping ^a   Luo, Zhiguo ^a   Chang, Jianhua ^a   Wu, Xianghua ^a   Hong, Xiaonan ^a  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

Chop; Diffuse large B cell lymphoma; Thalidomide

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISOLONE; PROTEIN BCL 2; PROTEIN BCL 6; THALIDOMIDE; VINCRISTINE; ANTINEOPLASTIC AGENT; BCL2 PROTEIN, HUMAN; BCL6 PROTEIN, HUMAN; RITUXIMAB; TUMOR MARKER;

ACUTE CORONARY SYNDROME; ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER REGRESSION; CONSTIPATION; CONTROLLED STUDY; DIZZINESS; DRUG EFFICACY; DRUG POTENTIATION; ECG ABNORMALITY; FATIGUE; FOLLOW UP; HUMAN; HYPERTRANSAMINASEMIA; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MUCOSA INFLAMMATION; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PARESTHESIA; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RASH; SINUS BRADYCARDIA; SINUS TACHYCARDIA; SOMNOLENCE; THROMBOCYTOPENIA; TREATMENT RESPONSE; TREMOR; URINE INCONTINENCE; VOMITING; CHEMISTRY; CHINA; CLINICAL TRIAL; COMPARATIVE STUDY; DIFFUSE LARGE B CELL LYMPHOMA; DISEASE FREE SURVIVAL; FEMALE; KAPLAN MEIER METHOD; MALE; MIDDLE AGED; MORTALITY; PATHOLOGY; REMISSION; TIME FACTOR; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, TUMOR; CHINA; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; PREDNISOLONE; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-BCL-6; REMISSION INDUCTION; RITUXIMAB; THALIDOMIDE; TIME FACTORS; TREATMENT OUTCOME; VINCRISTINE;

EID: 84973572560     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.8973     Document Type: Article

References (35)

1. Wing CC, James O. Randy G, Joseph C, Pauline C, Peter J, Andrew N, Andrew T, Ennio P, Franco C, Francoise B, Bertrand C, Faith H, et al. A clinical evaluation of the International Lymphoma Study group classification of Non- Hodgkin's lymphoma. Blood. 1997; 89:3909-18.
2. Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, Glick JH, Coltman CA, Miller TP. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med.1993; 328:1002-6.
3. Gaynor ER, Unger JM, Miller TP, Grogan TM, White LA, Mills GM, Balcerzak SP, Varterasian M, LeBlanc M, Fisher RI. Infusional CHOP chemotherapy (CVAD) with or without chemosensitizers offers no advantage over standard CHOP therapy in the treatment of lymphoma: a Southwest Oncology Group study. J Clin Oncol. 2001; 19:750-755.
4. Osby E, Hagberg H, Kvaløy S, Teerenhovi L, Anderson H, Cavallin-Stahl E, Holte H, Myhre J, Pertovaara H, Björkholm M. Nordic Lymphoma Group. CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment: results of a Nordic Lymphoma Group randomized trial. Blood. 2003; 101:3840-3848.
5. Fisher RI, Miller TP, O'Connor OA. Diffuse aggressive lymphoma. Hematology. 2004; 2004:221-36.
6. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van D, Neste E, Salles G, Gaulard P, Reyes F, Lederlin P, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B cell lymphoma. N Engl J Med. 2002; 346:235-42.
7. Pfreundschuh M, Trümper L, Osterborg A, Pettengell R, Trneny M, Imrie K, Ma D, Gill D, Walewski J, Zinzani PL, Stahel R, Kvaloy S, Shpilberg O, et al. CHOP chemotherapy plus rituximab versus CHOP chemotherapy alone in young patients with good-prognosis diffuse large- B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006; 7:379-91.
8. Gratzinger D, Zhao S, Marinelli RJ, Kapp AV, Tibshirani RJ, Hammer AS, Hamilton-Dutoit S, Natkunam Y. Microvessel density and expression of vascular endothelial growth factor and its receptors in diffuse large B cell lymphoma subtypes. Am J Pathol. 2007; 170:1362-1369.
9. Shaffer AL, Rosenwald A, Staudt LM. Lymphoid malignancies: the dark side of B-cell differentiation. Nat Rev Immunol; 2002; 2: 920-32.
10. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X, Powell JI, Yang L, Marti GE, et al. Distinct types of diffuse large-B cell lymphoma identified by gene expression profiling. Nature. 2000; 403:503-511.
11. Davis RE, Brown KD, Siebenlist U, Staudt LM. Constitutive nuclear factor kappaB activity is required for survival of Activated B Cell-like Diffuse Large B Cell lymphoma cells. J Exp Med. 2001; 194:1861-74.
12. D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA. 1994; 91:4082-4085.
13. Haslett PA, Corral LG, Albert M, Kaplan G. Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic respongse in the CD8+ subset. J Exp Med. 1998; 187:1885-92.
14. Davies FE, Raje N, Hideshima T, Lentzsch S, Young G, Tai YT, Lin B, Podar K, Gupta D, Chauhan D, Treon SP, Richardson PG, Schlossman RL, et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood. 2001; 98:210-6.
15. Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Richardson PG, Hideshima T, Munshi NC, Treon SP, Anderson KC. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood. 2002; 99:4525-4530.
16. Khan ZH, Simpson EJ, Cole AT, Holt M, MacDonald I, Pye D, Austin A, Freeman JG. Oesophageal cancer and cachexia: the effect of short-term treatment with thalidomide on weight loss and lean body mass. Aliment Pharmacol Ther. 2003; 17:677-682.
17. Keifer JA, Guttridge DC, Ashburner BP, Baldwin AS Jr. Inhibition of NF-kappa B activity by thalidomide through suppression of I kappa B kinase activity. J Biol Chom. 2001; 276:22382-22387.
18. Kaufmann H, Raderer M, Wöhrer S, Püspök A, Bankier A, Zielinski C, Chott A, Drach J. Antitumor activity of rituximab plus thalidomide in patients with relapsed/ refractory mantle cell lymphoma. Blood. 2004; 104:2269-71.
19. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-López A, Hagenbeek A, Cabanillas F, Klippensten D, Hiddemann W, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol. 1999; 17:1244.
20. Lin TY, Zhang HY, Huang Y, Guan ZZ, Shen T, Shi YK, Zhu J, Ke XY, Wang HQ, Shen ZX, Yu SY, Liu T, Shi XL. Comparison between R-CHOP regimen and CHOP regimen in treating naive diffuse large B-cell lymphoma in China-a multi-center randomized trail. Ai Zheng. 2005; 24:1421-6.
21. Wu HJ, Zhang QY, Chen DF, Guan XJ, Zhang BL, Ma J. Comparison of rituximab plus CHOP regimen and CHOP regimen alone for treatment of newly diagnosed patients with diffuse large B-cell lymphoma. Ai Zheng. 2005; 24:1498-502.
22. Shipp MA, Harrington DP, Anderson JR, Armitage JO, Bonadonna G, Brittinger G, Cabanillas F, Canellos GP, Coiffier B, Connors JM, Cowan RA, Crowther D, Dahlberg S. et al. A predictive model for aggressive Non-Hodgkin's lymphoma. N Engl J Med.1993; 329:987-994.
23. Urbauer E, Kaufmann H, Nösslinger T, Raderer M, Drach J. Thromboembolic events during treatment with thalidomide. Blood. 2002; 99:4247-8.
24. Zheng W, Wei G, Ye X, He J, Li L, Wu W, Shi J, Zhang J, Huang W, Xie W, Luo Y, Xue X, Lin M, et al. Bortezomib in combination with dexamethasone and subsequent thalidomide for newly-diagnosed multiple myeloma: a Chinese experience. Leuk Res. 2009; 33:1615-8.
25. Maeshima AM, Taniguchi H, Fukuhara S, Morikawa N, Munakata W, Maruyama D, Kim SW, Watanabe T, Kobayashi Y, Tobinai K, Tsuda H. Bcl-2, Bcl-6, and the International Prognostic Index are prognostic indicators in patients with diffuse large B-cell lymphoma treated with rituximab containing chemotherapy. Cancer Sci. 2012; 103: 1898-1904.
26. Gascoyne RD, Adomat SA, Krajewski S, Krajewska M, Horsman DE, Tolcher AW, O'Reilly SE, Hoskins P, Coldman AJ, Reed JC, Connors JM. Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma. Blood. 1997; 90:244-51.
27. Lossos IS, Jones CD, Warnke R, Natkunam Y, Kaizer H, Zehnder JL, Tibshirani R, Levy R. Expression of a single gene, BCL-6, strongly predicts survival in patients with diffuse large B-cell lymphoma. Blood. 2001; 98: 945-51.
28. Lossos IS, Czerwinski DK, Alizadeh AA, Wechser MA, Tibshirani R, Botstein D, Levy R. Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N Engl J Med. 2004; 350:1828-37.
29. Zeng LP, Wen YL, Ma Y, Wang GQ, Li Y, Wang J, Xu LL, Zhang XM. Mechanism and clinical significance of anti-apoptotic gene bcl-2 expression in diffuse large B-cell lymphoma. Zhonghua Bing Li Xue Za Zhi. 2011; 40:377-81.
30. Hernandez-Ilizaliturri FJ, Deeb G, Zinzani PL, Pileri SA, Malik F, Macon WR, Goy A, Witzig TE, Czuczman MS. Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype. Cancer. 2011;117:5058-5066.
31. Nowakowski GS, LaPlant B, Macon WR, Reeder CB, Foran JM, Nelson GD, Thompson CA, Rivera CE, Inwards DJ, Micallef IN, Johnston PB, Porrata LF, Ansell SM, et al. Lenalidomide Combined With R-CHOP Overcomes Negative Prognostic Impact of Non-Germinal Center B-Cell Phenotype in Newly Diagnosed Diffuse Large B-Cell Lymphoma: A Phase II Study. J Clin Oncol. 2015; 33:251-257.
32. Johnston KM, Marra CA, Connors JM, Najafzadeh M, Sehn L, Peacock SJ. Cost-effectiveness of the addition of rituximab to CHOP chemotherapy in first-line treatment for diffuse large B-cell lymphoma in a population-based observational cohort in British Columbia, Canada. Value Health. 2010; 13:703-11.
33. Hornberger JC, Best JH. Cost utility in the United States of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for the treatment of elderly patients with diffuse large B-cell lymphoma. Cancer. 2005;103:1644-51.
34. Groot MT, Lugtenburg PJ, Hornberger J, Huijgens PC, Uyl-de Groot CA. Cost-effectiveness of rituximab (MabThera) in diffuse large B-cell lymphoma in The Netherlands. Eur J Haematol. 2005; 74:194-202.
35. Khor S, Beca J, Krahn M, Hodgson D, Lee L, Crump M, Bremner KE, Luo J, Mamdani M, Bell CM, Sawka C, Gavura S, Sullivan T, et al. Real world costs and cost-effectiveness of Rituximab for diffuse large B-cell lymphoma patients: a population-based analysis. BMC Cancer. 2014; 14:586-596.